melanoma, as well as cancers of the lung and colon. Separately, the company announced that it had chosen Raleigh, NC-based INC Research (NASDAQ: [[ticker:INCR]]) to be a contract research organization for an upcoming clinical trial of a Cellectar drug candidate that it has said has the potential to treat multiple myeloma.
—Build Madison, a free 24-hour “hackathon” for artists, engineers, software developers, and anyone who enjoys creating something from nothing, will take place this weekend at the maker space Sector67. The event will kick off with some pitches from some of the participants, and that will allow others who aren’t set on projects to find ones that interest them. From there, teams will get to work, then discuss what they accomplished and learned at a wrap-up session on Sunday. For more Build Madison coverage, check out this preview in the Wisconsin State Journal.
